Time-of-flight mass spectrometry analysis of the ferroportin-hepcidin binding domain complex for accurate mass confirmation of bioactive hepcidin 25

Clinica Chimica Acta

Volumn 411, Issue 5-6, 2010, Pages 453-455

  Crockett, David K ^a   Kushnir, Mark M ^a   Phillips, John D ^b   Rockwood, Alan L ^a  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN; HEPCIDIN; HEPCIDIN 25; METHIONINE; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; CENTRIFUGATION; FREEZE DRYING; GENE MUTATION; HUMAN; LETTER; MOLECULAR WEIGHT; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

ANTIMICROBIAL CATIONIC PEPTIDES; BINDING SITES; CATION TRANSPORT PROTEINS; HUMANS; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 75149136101     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.11.031     Document Type: Letter

References (17)

1. Swinkels D.W., and Wetzels J.F. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23 (2008) 2450-2453
2. Zaritsky J., Young B., Wang H.J., et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4 (2009) 1051-1056
3. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 46 (2006) 554-557
4. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
5. Katodritou E., Ganz T., Terpos E., et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol 84 8 (2009) 524-526
6. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100 (2009) 9-16
7. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004) 77-82
8. Kushnir M.M., Rockwood A.L., Nelson G.J., Yue B., and Urry F.M. Assessing analytical specificity in quantitative analysis using tandem mass spectrometry. Clin Biochem 38 (2005) 319-327
9. Singh R.J., Grebe S.K., Yue B., et al. Precisely wrong? Urinary fractionated metanephrines and peer-based laboratory proficiency testing. Clin Chem 51 (2005) 472-473 [discussion 473-474]
10. Pollack A. The New York Times (2009)
11. Kroot J., EK, Bansal S., et al. 2009 International BioIron Society (IBIS) meeting (2009), Porto, Portugal p. Abstract 43
12. Kemna E., Tjalsma H., Laarakkers C., et al. Novel urine hepcidin assay by mass spectrometry. Blood 106 (2005) 3268-3270
13. Kemna E.H., Tjalsma H., Podust V.N., and Swinkels D.W. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53 (2007) 620-628
14. Jordan J.B., Poppe L., Haniu M., et al. Hepcidin revisited: disulfide connectivity, dynamics, and structure. J Biol Chem 284 (2009) 24155-24167
15. Diamandis E.P., Hanash S., Lopez M., Carr S., and Petricoin III E.F. Protein quantification by mass spectrometry: is it ready for prime time?. Clin Chem 55 (2009) 1427-1430
16. De Domenico I., Nemeth E., Nelson J.M., et al. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab 8 (2008) 146-156
17. Merrell K., Southwick K., Graves S.W., et al. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 15 (2004) 238-248